Skye Bioscience Inc
NASDAQ:SKYE

Watchlist Manager
Skye Bioscience Inc Logo
Skye Bioscience Inc
NASDAQ:SKYE
Watchlist
Price: 5.39 USD -2% Market Closed
Market Cap: 163.5m USD
Have any thoughts about
Skye Bioscience Inc?
Write Note

Skye Bioscience Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Skye Bioscience Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Skye Bioscience Inc
NASDAQ:SKYE
Operating Income
-$43.3m
CAGR 3-Years
-89%
CAGR 5-Years
-50%
CAGR 10-Years
-116%
Abbvie Inc
NYSE:ABBV
Operating Income
$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.9B
CAGR 3-Years
-3%
CAGR 5-Years
20%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.3B
CAGR 3-Years
17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
13%
CAGR 10-Years
18%

See Also

What is Skye Bioscience Inc's Operating Income?
Operating Income
-43.3m USD

Based on the financial report for Jun 30, 2024, Skye Bioscience Inc's Operating Income amounts to -43.3m USD.

What is Skye Bioscience Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-116%

Over the last year, the Operating Income growth was -259%. The average annual Operating Income growth rates for Skye Bioscience Inc have been -89% over the past three years , -50% over the past five years , and -116% over the past ten years .

Back to Top